Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 29 November 1985:
Vol. 230. no. 4729, p. 992
DOI: 10.1126/science.230.4729.992-c
Prev | Table of Contents | Next

Articles

Erratum

In the letter by M. F. Balandrin and J. A. Klocke (13 Sept., p. 1036), it was incorrectly stated that nabilone (Cesamet) has been approved for marketing by the Food and Drug Administration. Nabilone has not yet been approved by the FDA. The synthetic cannabinoid recently approved is in fact dronabinol (Marinol), a synthetic form of delta-9-tetra-hydrocannabinol. In the same letter, the affiliation of the authors should have been Native Plants, Inc., not Nature Plants, Inc. In the original article by Balandrin et al. (7 June, p. 1154), references 23 and 65 were incorrect. They should have been as follows: 23. Y. Aharonowitz and G. Cohen, Sci. Am. 245, 140 (September 1981); 65. D. E. Eveleigh, Sci. Am. 245, 154 (September 1981).

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)